SPH.L

Sinclair Pharma Plc
Sinclair Pharma PLC - Rule 2.9 Announcement
2nd November 2018, 12:36
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2122G
Sinclair Pharma PLC
02 November 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

2 November 2018

Sinclair Pharma plc

("Sinclair" or the "Company")

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at 08:00 am on 2 November 2018, it had 517,657,084 ordinary shares of 1 pence each in issue and admitted to trading on AIM.  No ordinary shares are held in treasury.  Accordingly, the total number of voting rights in Sinclair is 517,657,084.  The International Securities Identification Number ("ISIN") for Sinclair's ordinary shares is GB0033856740.

 

For further information, please contact:

Sinclair Pharma plc 

+44 (0) 20 7467 6920

Chris Spooner


Alan Olby


Andy Crane




Rothschild (Lead Financial Adviser to Sinclair)

+44 (0) 20 7280 5000

Dominic Hollamby


Julian Hudson

Josh Johnson


 

 

Peel Hunt LLP (Joint Financial Adviser, NOMAD and Joint Broker to Sinclair)

 

 

+44 (0)20 7418 8900

James Steel


Michael Nicholson


Oliver Jackson




FTI Consulting (Public Relations Adviser to Sinclair)

+ 44 (0) 203 727 1000

Ben Atwell


Brett Pollard


Stephanie Cuthbert


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RTTBTBTTMBJMBIP ]]>
TwitterFacebookLinkedIn